Shares of iCAD Inc (NASDAQ:ICAD) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.60 and traded as high as $7.67. iCAD shares last traded at $7.64, with a volume of 8,311 shares.
Separately, ValuEngine cut shares of iCAD from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.
The company has a market capitalization of $145.39 million, a P/E ratio of -19.79 and a beta of 1.18. The firm’s 50 day moving average price is $7.10 and its two-hundred day moving average price is $6.60. The company has a current ratio of 1.76, a quick ratio of 1.62 and a debt-to-equity ratio of 2.00.
iCAD (NASDAQ:ICAD) last issued its quarterly earnings results on Wednesday, October 30th. The technology company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). The company had revenue of $7.86 million during the quarter, compared to analysts’ expectations of $7.43 million. iCAD had a negative net margin of 46.85% and a negative return on equity of 76.99%. Analysts anticipate that iCAD Inc will post -0.58 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of ICAD. Tower Research Capital LLC TRC bought a new position in shares of iCAD during the 2nd quarter worth approximately $54,000. Cadence Capital Management LLC bought a new position in shares of iCAD in the third quarter valued at $73,000. Worth Venture Partners LLC bought a new position in shares of iCAD in the second quarter valued at $92,000. Virtu Financial LLC bought a new position in shares of iCAD in the third quarter valued at $106,000. Finally, United Capital Financial Advisers LLC grew its stake in shares of iCAD by 6.7% in the second quarter. United Capital Financial Advisers LLC now owns 57,765 shares of the technology company’s stock valued at $368,000 after buying an additional 3,625 shares in the last quarter. 25.39% of the stock is owned by institutional investors.
iCAD Company Profile (NASDAQ:ICAD)
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Featured Story: What is Depreciation?
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.